This article is more than 5 years old. Information may no longer be current.
Takeda Partners with University of Chicago, Mount Sinai in IBD Research
Takeda announced it has partnered with The University of Chicago and Icahn School of Medicine at Mount Sinai for a 3-year research initiative focused on digital innovation and immunology in inflammatory bowel disease, according to a press release.
“Creating strong partnerships with the potential to discover game changing technologies and health solutions is a key priority for our company,” Charlie Baum, MD, Takeda’s vice president and head of U.S. Medical and Scientific Affairs, said in the press release. “This research assures continued scientific focus and exploration to help people affected by IBD, a chronic, challenging to treat disease that impacts as many as 1.6 million Americans and 5 million people globally.”
The University of Chicago aims to develop a patient–physician digital platform that can communicate disease status in real-time, organize individual factors affecting each patient (environmental, molecular, genetic, microbiome), and enable a system to identify personalized therapy with patients with IBD.
David T. Rubin
Jean-Frédéric Colombel
“We are very grateful for Takeda’s vision and support in accelerating novel research of and care for people suffering from IBD,” David T. Rubin, MD, the Joseph B. Kirsner Professor of Medicine, chief of the section of gastroenterology, hepatology and nutrition at The University of Chicago Medicine, and Healio Gastroenterology Peer Perspective Board member, said in the press release.
Concurrently, Mount Sinai aims to discover novel paradigms of lymphocytic homing to the colon, as well as the role of the microbiome in colonic homing and therapeutic cell-based approaches for suppressing inflammation of the intestine, according to the press release.
“A partnership between Takeda and Mount Sinai could lead to identifying novel homing markers to the large bowel and define innovative therapeutic targets in patients with IBD,” Jean-Frédéric Colombel, MD, Director of the Leona M. and Harry B. Helmsley Charitable Trust Inflammatory Bowel Disease Center at Icahn School of Medicine at Mount Sinai, said in the press release.
Through information and resource sharing, addressing data gaps and research collaborations, this partnership aims to advance understanding of novel therapies and treatment paradigms, according to the press release.
Disclosure: Baum is employed by Takeda.